Between June 3-6, 2019 Pharmahungary Group scientific team as well as Founder & CEO attended the International Society for Heart Research (ISHR) World Congress organized in Beijing, China. The presentation of Prof. Peter Ferdinandy, MD, PhD, MBA related to Pharmahungary Group’s innovative in-house R&D project miRNAtarget entitled: “MicroRNA interaction network in the hypercholesterolemic heart: unbiased way to identify molecular targets”.
Pharmahungary Group scientific team has presented 2 posters titled:
– Hidden cardiotoxic effect of rofecoxib can be unmasked in an ex vivo model of simulated ischemia/reperfusion injury. Poster connected to Pharmahungary Group innovative in-house R&D project, Hiddentox.
– Obesity inhibits effects of selegiline on cardiac mitochondrial function and quality control
For more information on our innovative in-house R&D projects including miRNAtarget and Hiddentox please see http://www.pharmahungary.com/pipeline and https://mirnatarget.com.
For more information on our innovative preclinical and clinical R&D services contact us directly at: